NeoGenomics, Inc.

NASDAQ:NEO

Medical - Diagnostics & Research

Healthcare
$15.29 +6.03%

+$0.63 today

Market cap
$1.99B
Beta
1.81
P/E (TTM)
-2.9
EPS (TTM)
-$3.84
52W Low $4.72High $13.74

Volume 1.09M

Average 1.94M

NEO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

NeoGenomics, Inc.NASDAQ: NEO

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit growth accelerates

Q2 FY2026 gross profit of $91.88M rose 18.9% year over year, ahead of the +8.7% change in trailing-twelve-month gross profit. Sequentially, it rose 13.6% from the prior quarter. Over 3 fiscal years it compounded at +14.6% a year.

Context

  • Gross profit amounted to 38.8% of revenue in FY2025, down 5.1 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +18.9% holds above the trailing-twelve-month pace of +8.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$91.88M+13.6% QoQ
Last fiscal yearDec 2025
$282.54M-2.6% YoY
LTMJun 2026
$328.9M+8.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.9%——
1 year-2.6%——
3-year CAGR+14.6%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
282.54M USD
Year-over-year change
-2.6%
4-year CAGR
+10.9%

Gross Profit vs competitors

How NEO compares with its peers on the latest reported figures

  • NEO's LTM Jun 2026 gross profit of $328.9M is the 4th highest of the 10 companies compared; the peer median is $261.97M.
  • Its year-over-year change of +8.7% is the 7th highest of 10, against a peer median of +23.9%.
  • Gross profit amounts to 42.9% of revenue for NEO, versus a peer median of 68.2%.
NEO Competitors Peer median
Gross Profit for NEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$833.7M +44.9%+29.2%65.2%
MYGNMyriad Genetics, Inc.LTM Mar 2026$580M -0.3%+6.6%70.0%
VCYTVeracyte, Inc.LTM Jun 2026$405.1M +23.9%+22.7%72.1%
NEONeoGenomics, Inc.LTM Jun 2026$328.9M +8.7%+14.6%42.9%
WGSGeneDx Holdings Corp.LTM Jun 2026$309.9M +27.3%—68.2%
CSTLCastle Biosciences, Inc.LTM Mar 2026$261.97M -7.9%+37.5%77.1%
BDSXBiodesix, Inc.LTM Mar 2026$78.88M +35.1%+44.0%82.1%
XGNExagen Inc.LTM Mar 2026$39.88M +18.6%+22.0%58.3%
PSNLPersonalis, Inc.LTM Mar 2026$8.85M -69.0%—13.7%
GRALGRAIL, Inc.LTM Jun 2026-$17.89M +76.4%—10.8%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding NEO) $261.97M+23.9%+26.0%68.2%

Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue484.33M509.73M591.64M660.57M727.33M
Cost of Revenue297.27M321.83M347.04M370.47M444.79M
Gross Profit187.06M187.9M244.6M290.1M282.54M
Gross Margin38.6%36.9%41.3%43.9%38.8%
Research & Development21.87M30.33M27.31M31.16M37.08M
Selling, General & Admin283.94M277.91M279.96M310.49M365.34M
Operating Expenses305.81M345.52M352.34M382.21M348.62M
Depreciation & Amortization53.35M69.43M72.58M72.55M67.82M
EBITDA46.5M(82.33M)(17.61M)(1.51M)(38.69M)
EBITDA Margin9.6%-16.2%-3.0%-0.2%-5.3%
Operating Income(118.75M)(157.62M)(107.74M)(92.11M)(66.08M)
Operating Margin-24.5%-30.9%-18.2%-13.9%-9.1%
Interest Income3.14M6.08M16.9M18.43M9.07M
Interest Expense8.22M7.58M6.91M6.62M3.75M
Other Income / Expenses103.68M(1.72M)10.64M11.43M(44.19M)
Income Before Tax(15.08M)(159.34M)(97.1M)(80.68M)(110.27M)
Pre-Tax Margin-3.1%-31.3%-16.4%-12.2%-15.2%
Income Tax Expense(6.73M)(15.09M)(9.13M)(1.95M)(2.24M)
Net Income(8.35M)(144.25M)(87.97M)(78.73M)(108.03M)
Net Margin-1.7%-28.3%-14.9%-11.9%-14.9%
EPS (Basic)(0.07)(1.16)(0.70)(0.62)(0.84)
EPS (Diluted)(0.07)(1.16)(0.70)(0.62)(0.84)
Weighted Avg Shares119.96M124.22M125.5M126.66M128.1M
Weighted Avg Shares (Diluted)119.96M124.22M125.5M126.66M128.1M

NeoGenomics, Inc.

NASDAQ:NEO

Intrinsic Alpha fair value

Locked

Current Price

$15.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.